Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort

被引:8
|
作者
Rumpold, H. [1 ]
Kirchweger, P. [1 ,2 ]
Niedersuss-Beke, D. [3 ]
Falch, D. [3 ]
Wundsam, H. [4 ]
Metz-Gercek, S. [5 ]
Piringer, G. [2 ,6 ]
Thaler, J. [6 ]
机构
[1] Ordensklinikum Linz, Gastrointestinal Canc Ctr, Seilerstaette 4, A-4010 Linz, Austria
[2] Johannes Kepler Univ Linz, Med Fac, Linz, Austria
[3] Wilhelminenspital Stadt Wien, Dept Internal Med 1, Vienna, Austria
[4] Ordensklinikum Linz, Dept Gen & Visceral Surg, Linz, Austria
[5] Clin Canc Ctr Upper Austria, Linz, Austria
[6] Hosp Wels Grieskirchen, Dept Internal Med 4, Wels, Austria
关键词
Colorectal cancer; real-life; metastasis; prognosis; treatment; PULMONARY METASTASES; RESECTION;
D O I
10.1080/0284186X.2020.1837945
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Metastatic patterns have been linked with prognosis in colorectal cancer. We aim to determine the distribution of metastases, their dynamics during disease and their prognostic impact for specific clinical treatment scenarios (resection of metastasis and/or systemic treatment, best supportive care). Material and methods 978 patients diagnosed with metastatic colorectal adenocarcinoma treated at three oncological centers from 2006 to 2018 were included. Overall survival was assessed depending on tumor load, distribution of metastases and treatment of the patients. Results Most patients had single site metastasis (n = 684; 69.9%): 398 patients had liver (n = 398; 40.7%) and 103 patients had lung only metastasis (10.6%). The number of organs involved in metastases at diagnosis was highly prognostic (HR 0.77; CI 0.65, 0.90), whereas the additional gain of metastases during progression of the disease was not. The majority of patients (62.9-74.2%) with initial lung, liver or both metastases retained their initial metastatic status. In the overall population, lung only metastases were associated with the most favorable outcome (HR 0.64; CI 0.50, 0.81). This was also observed in patients receiving best supportive care (HR 0.45; CI 0.27, 0.75). Resection of lung only metastases resulted in longer median survival (102.2 months). A relevant survival difference in patients treated by systemic therapy alone was not observed. Lung only metastasis was associated with rectal cancer (p < .001) and RAS-mutation (p = .01); both, lung and liver metastasis were associated with time from diagnosis to first metastasis (p < .001). Conclusion The number of organs involved in metastasis at diagnosis but not the total cumulative number of involved organs is of prognostic relevance in colorectal adenocarcinoma. This prognostic relevant initial metastasis distribution remains unchanged in the majority of patients during the disease. However, the prognostic impact of the metastatic pattern is potentially altered by treatment modality.
引用
收藏
页码:180 / 186
页数:7
相关论文
共 50 条
  • [21] Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)
    Dano, D.
    Lardy-Cleaudy, A.
    Monneury, A.
    Quenel-Tueux, N.
    Levy, C.
    Mouret-Reynier, M. -A.
    Coudert, B.
    Mailliez, A.
    Ferrero, J. -M.
    Guiu, S.
    Campone, M.
    Rouge, T. De la Motte
    Petit, T.
    Pistilli, B.
    Dalenc, F.
    Simon, G.
    Lerebours, F.
    Chabaud, S.
    Bertucci, F.
    Goncalves, A.
    ESMO OPEN, 2021, 6 (04)
  • [22] Comparison of the prognostic value of prognostic nutritional index in colorectal cancer deaths:a retrospective cohort study
    Zhou, Hongqi
    Wang, Wenling
    Zhang, Ruyi
    Dong, Hongmin
    Wang, Gang
    Chen, Weiwei
    LI, Guodong
    FOOD SCIENCE AND TECHNOLOGY, 2022, 42
  • [23] Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit
    Luca Bertero
    Rosella Spadi
    Simona Osella-Abate
    Sara Mariani
    Isabella Castellano
    Alessandro Gambella
    Patrizia Racca
    Mario Morino
    Paola Cassoni
    World Journal of Surgical Oncology, 18
  • [24] Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit
    Bertero, Luca
    Spadi, Rosella
    Osella-Abate, Simona
    Mariani, Sara
    Castellano, Isabella
    Gambella, Alessandro
    Racca, Patrizia
    Morino, Mario
    Cassoni, Paola
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [25] Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
    Salaun, Helene
    de Koning, Leanne
    Saint-Ghislain, Mathilde
    Servois, Vincent
    Ramtohul, Toulsie
    Garcia, Agathe
    Matet, Alexandre
    Cassoux, Nathalie
    Mariani, Pascale
    Piperno-Neumann, Sophie
    Rodrigues, Manuel
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [26] Predictive and prognostic factors in metastatic colorectal cancer patients treated with fruquintinib: A multicenter real-world analysis
    Zhang, C.
    Wang, Y.
    Xu, J.
    Dong, M.
    Liu, K.
    Lu, Y.
    Chen, K.
    Cao, Y.
    Shi, H.
    Bei, Y.
    Li, J.
    Zhao, J.
    Cao, Y.
    Lu, N.
    Liu, H.
    Cai, P.
    Li, K.
    Yang, T.
    He, N.
    Dong, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S44 - S44
  • [27] Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors
    Wang, Yi
    Xu, Jianfen
    Dong, Mingjun
    Liu, Kaitai
    Lu, Yi
    Chen, Ke
    Cao, Yuepeng
    Shi, Hang
    Bei, Yanping
    Li, Jianjiong
    Zhao, Jianpei
    Cao, Yisheng
    Lu, Ning
    Yang, Lu
    Liu, Haizhong
    Cai, Ping
    Li, Kai
    Yang, Tong
    He, Ning
    Dong, Jing
    Zhang, Chen
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1519 - 1533
  • [28] Pattern of Bevacizumab (BV) Use in 1st-Line Therapy Metastatic Colorectal Cancer (mCRC) in Real-Life Practice: Results of the ETNA Cohort Study
    Fourrier-Reglat, A.
    Smith, D.
    Ravaud, A.
    Rouyer, M.
    Balestra, A.
    Jayles, D.
    Moore, N.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S112 - S112
  • [29] Prognostic impact of primary tumor location on synchronous and metachronous colorectal liver metastases: A retrospective monocentric real-life analysis
    Signorelli, C.
    Chilelli, M.
    Amodio, P.
    Schirripa, M.
    Sperduti, I.
    Santoro, R.
    Ranalli, T.
    Pessina, G.
    Natoni, F.
    Virtuoso, A.
    Berrios, J. Giron
    Mazzotta, M.
    Nelli, F.
    Fabbri, M.
    Primi, F.
    Marrucci, E.
    Ruggeri, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S351 - S352
  • [30] Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review
    Gotfrit, J.
    Vickers, M.
    Sud, S.
    Asmis, T.
    Cripps, C.
    Goel, R.
    Hsu, T.
    Jonker, D.
    Goodwin, R.
    CURRENT ONCOLOGY, 2017, 24 (04) : 234 - 239